Son et al., have introduced the concept of using HSA to guide siRNA delivery to tumors, through nanocarriers formed by disulfide-crosslinking between thiolated HSA and polymerized siRNA, and have reported increased in vivo accumulation of the nanocarriers at the tumor sites [20]. Here, ALB is linked to neoplasm.